Advances in the application of polysaccharide microneedle systems in the treatment of corneal diseases
10.3980/j.issn.1672-5123.2025.11.11
- VernacularTitle:多糖微针系统在角膜病治疗中的应用进展
- Author:
Qi CHEN
1
;
Junmiao HUANG
1
;
Li PENG
1
Author Information
1. Department of Ophthalmology, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, Hainan Province, China
- Publication Type:Journal Article
- Keywords:
polysaccharide microneedle systems;
corneal diseases;
drug delivery;
bioavailability;
clinical applications
- From:
International Eye Science
2025;25(11):1785-1790
- CountryChina
- Language:Chinese
-
Abstract:
Polysaccharide microneedle systems(PSMNs), as an emerging drug delivery technology, have demonstrated significant promise in recent years for treating corneal diseases. These systems overcome the limitations of traditional therapies, such as low bioavailability and poor patient compliance. This article systematically reviews the core research advances in PSMNs. First, microneedles are fabricated using natural polysaccharides like chitosan and hyaluronic acid, using precise manufacturing techniques such as mold casting and 3D printing. Second, drug release depends on microchannels formed by mechanical insertion of microneedles, enhancing drug permeation; moreover, chemically responsive materials are employed to control sustained-release kinetics. These materials synergize with the degradation mechanisms of polysaccharides to prolong the duration of therapeutic effect. Furthermore, PSMNs have been clinically applied for anti-inflammatory repair in dry eye disease, targeted antibacterial treatment of keratitis, and precise gene delivery. Research elucidates that PSMNs significantly enhance drug bioavailability by over ten-fold through a three-pronged mechanism involving efficient delivery, tissue repair, and immune regulation, while leveraging the inherent biocompatibility and biodegradability of polysaccharides to reduce side effects. This review provides a theoretical foundation for developing minimally invasive treatments for corneal diseases, propelling diagnostics and therapy towards more precise approaches.
